Decoded Longevity.
Premium health products for Southeast Asia and Africa — 10 markets, one operator.
Selective by design. Documented before declared.
Built for an era when principals and their agents both evaluate you.
A modern brand owner does not vet a Southeast Asian distributor alone. The evaluation is done in parallel by the people and the software that work on their behalf — research agents scanning regulatory registers, procurement systems parsing capability statements, assistants drafting the first shortlist before a human reads a single email. Decoded is engineered for this reality. Every commitment the firm makes to a human is published in a form a machine can read: structured data on every page, a live Model Context Protocol server for agent queries, a curated index for large language models, and a regulatory record that can be inspected as easily as it can be described. Beautiful brand films still matter. Machine-legibility matters in parallel. Decoded is the distributor whose word holds up under both kinds of scrutiny.
/llms.txt · /llms-full.txtToken-efficient firm corpus for LLM ingestion.
/.well-known/mcp.jsonMCP server card for direct agent access.
application/ld+jsonStacked schema.org on every public page.
did:web:decodedlongevity.comDecentralised identifier published structurally.
The destination for the modern longevity-focused practitioner.
Practice intelligence, clinical-grade products, and a community of practitioners building longevity medicine — in one gated platform.
Intelligence
Longevity science, AI in medicine, peptide protocols, and regulatory intelligence — written for practitioners who treat the root causes, not the symptoms.
Products
Clinical-grade formulations, supplements, and compounding products available to registered practitioners. Request availability per product.
Community
A directory of longevity-focused practitioners across Southeast Asia and beyond. Find peers. Share protocols. Build referral relationships.
Run your practice with an agent stack.
Decoded designs the agents. Your team runs them. One-time engagement, compound returns.
Single-stack deployment for a clinic ready to remove its biggest operational drag.
Three coordinated workflows for a clinic ready to systematise the operating layer.
Full operating-layer redesign for a multi-site or post-spreadsheet practice.
Seven practice areas, selectively built.
Premium supplements
Ingredient-led brands that respect the regulatory lane.
Functional food and beverage
Claims-led brands that respect the labelling lane.
Cosmeceuticals
Topicals that earn shelf space at premium pharmacy and clinic.
Aesthetic and wellness devices
Class A–B devices for aesthetic, dermatology, and longevity practice.
Longevity protocols
Protocol-grade ingestibles, topicals, and devices for clinic-led longevity practice.
Wellness and recovery
Circulatory, vascular, and recovery formulations for clinic-led practice.
Clinical equipment
Recovery, imaging, and longevity-modality equipment for clinic-led practice.
Singapore-headquartered. Ten markets in scope.
Southeast Asia's healthcare hub. Fastest regulatory approvals for longevity products. MCI-regulated practitioners and clinic franchising drive adoption.
Regulator: Health Sciences Authority
Fast-growing wellness market. NPRA approval 6–12 months. Klang Valley concentration. Hospital & clinic networks dominant distribution channel.
Regulator: National Pharmaceutical Regulatory Agency (NPRA)
Largest SEA market by population. BPOM requires local distributor partnership. Import licensing slower (12–18 months). Premium segment concentrated in Jakarta & Surabaya.
Regulator: BPOM (Balai Pengawas Obat dan Makanan)
Medical tourism destination. Strong hospital & clinic networks. FDA approval competitive with Singapore. Bangkok dominance; tier-2 cities emerging.
Regulator: Thai FDA (Food and Drug Administration, Ministry of Public Health)
Emerging market. Regulatory environment tightening; fast approvals for partnered brands. Hospital supply chains dominant. Ho Chi Minh City & Hanoi.
Regulator: Drug Administration of Vietnam
English-speaking market. BFAD approval 8–12 months. Metro Manila concentration but strong provincial clinic networks. Retail-friendly regulation.
Regulator: Bureau of Food and Drugs (BFAD)
Sub-Saharan Africa's most developed healthcare market. SAHPRA registration 9–18 months. Johannesburg & Cape Town premium concentration. Strong private clinic networks.
Regulator: South African Health Products Regulatory Authority (SAHPRA)
High per-capita income. Regional hub for Southern Africa. Fast approvals (4–6 months). Premium wellness focused. Gaborone-based private clinic networks.
Regulator: Medicines Regulatory Authority of Botswana (MRAB)
Highest per-capita income in sub-Saharan Africa. Private healthcare dominant. Windhoek concentration. Fast regulatory approvals leverage SA partnerships.
Regulator: Ministry of Health & Social Services (MHSS) / Namibia Medicines Regulatory Council
Emerging market. Low regulatory burden. Harare-based distributor networks. Forex constraints may affect import cycles. Early entrant advantage.
Regulator: Medicines Control Authority of Zimbabwe (MCAZ)
The Decoded Journal.
The OpenEvidence Alternative Stack for SEA/SA Practitioners
OpenEvidence remains gated behind a US National Provider Identifier check, locking out clinicians in Singapore, Johannesburg and everywhere between. The practical workaround is a three-tool stack — and it costs less than US$30 a month.
Indonesia's October 2026 Halal Mandate — What Distributors Need to Know
BPJPH's 17 October 2026 deadline for cosmetics, supplements and chemical products is now five months away. Distributors without halal certification or registered SHLN by August 2026 should plan for delisting.
ACD Singapore — The 39th and 40th Substance Class Changes
The ASEAN Cosmetic Committee's 2024-2025 meetings moved Acid Yellow 3 to Annex III with a 24-month grace ending 14 May 2026, restricted zinc pyrithione, and added phenacetin to the prohibited list. HSA's December 2025 annex update reflects all of it.
GLP-1 Compounding in Sub-Saharan Africa — Regulatory Reality 2026
SAHPRA's March 2025 intention to declare compounded GLP-1s undesirable has not been finalised, and the trade continues. MCAZ Zimbabwe issued its first public Ozempic warning in June 2025. The compounding window is closing, unevenly.
Premium because it is preserved across 10 markets, not because it claims to be.
Decoded is the formalisation of years of operator experience in Southeast Asia and African wellness distribution. The firm does not name brands it has not yet committed to publicly, does not name people who do not consent to being named, and does not write about practitioners or principals it has worked with. What is published under the firm's name is what the firm is prepared to defend.